NoneFormer South Carolina Governor Nikki Haley isn’t on board with several of Trump’s Cabinet picks, she told listeners on her recent podcast episode of Nikki Haley Live. The former 2024 presidential candidate is concerned about some of Trump’s picks, but said she is looking at the policies for these nominations instead of personalities. She said Republican U.S. Rep. Matt Gaetz of Florida will have “a lot of issues,” getting confirmed as Attorney General. “It’s hard to start a confirmation when you have allegations of illicit drug use and sex parties with minors,” Haley said of Gaetz. “So that’s going to be difficult. The same goes for Pete Hegseth, who was accused of sexual assault.” Gaetz withdrew his name to be Attorney General on Thursday. “While the momentum was strong, it is clear that my confirmation was unfairly becoming a distraction to the critical work of the Trump/Vance Transition. There is no time to waste on a needlessly protracted Washington scuffle, thus I’ll be withdrawing my name from consideration to serve as Attorney General,” he posted on social media platform X. Gaetz has been accused of sexual misconduct allegations including having sex with a minor, which he has long denied. Haley said while the two have a right to defend themselves, they would have to answer to these allegations. Haley said Health and Human Services nominee, Robert F. Kennedy Jr., who also ran as a 2024 presidential candidate as an Independent, is “not a health guy.” “He is not educated, trained or practiced in health at all,” Haley said, after explaining the role HHS has on society and the branches it covers, like the FDA and National Institutes of Health. When Kennedy dropped out of the presidential election, he asked his supporters to back Trump. At the time, Trump signaled he would consider Kennedy for a role in his administration. Haley also detailed some of his strongly Democratic views, including his stance on climate change and abortion. She said Kennedy said his and Trump’s positions could not be “further apart.” “Why are we putting someone that’s so ideologically opposed to Donald Trump’s views and Republican views? Why do we want that? You know, but what else do we know about his views?” Haley asked. Haley served under the Trump administration as U.N. Ambassador during his first term in office. She and Trump had a tumultuous relationship during their time campaigning against one another, often calling each other names and trading insults. Haley, however, said she would be voting for Trump months after she dropped out, and Trump said Haley would be a part of his administration again “in some form,” while he was campaigning. However, once Trump was elected, he made a social media post that said Haley would not be returning to work with him. She also has “major issues” on the nomination of Tulsi Gabbard, who was nominated for Director of National Intelligence, Haley said Wednesday. Haley talked about Gabbard’s history of criticizing and disagreeing with Trump on various national intelligence proposals. She also questioned Gabbard decisions like going to Syria in 2017 for a “photo op” with Bashar al-Assad, the current president of Syria, who was massacring his own people, Haley said. “Now, this to me is disgusting,” Haley said. “You can go back and look at a speech I gave holding up pictures of dead children who had been killed by chemical attacks. Yup, choked to death.” She said the Department of National Intelligence analyzes real threats, and it is not a place for Russian, Iranian, Syrian or Chinese sympathizers. ©2024 The State. Visit thestate.com . Distributed by Tribune Content Agency, LLC.
By DEVNA BOSE One of the country’s largest health insurers reversed a change in policy Thursday after widespread outcry, saying it would not tie payments in some states to the length of time a patient went under anesthesia. Anthem Blue Cross Blue Shield said in a statement that its decision to backpedal resulted from “significant widespread misinformation” about the policy. “To be clear, it never was and never will be the policy of Anthem Blue Cross Blue Shield to not pay for medically necessary anesthesia services,” the statement said. “The proposed update to the policy was only designed to clarify the appropriateness of anesthesia consistent with well-established clinical guidelines.” Anthem Blue Cross Blue Shield would have used “physician work time values,” which is published by the Centers for Medicare and Medicaid Services, as the metric for anesthesia limits; maternity patients and patients under the age of 22 were exempt. But Dr. Jonathan Gal, economics committee chair of the American Society for Anesthesiologists, said it’s unclear how CMS derives those values. In mid-November, the American Society for Anesthesiologists called on Anthem to “reverse the proposal immediately,” saying in a news release that the policy would have taken effect in February in New York, Connecticut and Missouri. It’s not clear how many states in total would have been affected, as notices also were posted in Virginia and Colorado . Related Articles National News | The next census will gather more racial, ethnic information National News | As data centers proliferate, conflict with local communities follows National News | NASA’s stuck astronauts hit 6 months in space. Just 2 more to go National News | Imprisoned Proud Boys leader balks at answering a prosecutor’s questions about Capitol attack National News | National Weather Service cancels tsunami warning for the West Coast after 7.0 earthquake People across the country registered their concerns and complaints on social media, and encouraged people in affected states to call their legislators. Some people noted that the policy could prevent patients from getting overcharged. Gal said the policy change would have been unprecedented, ignored the “nuanced, unpredictable human element” of surgery and was a clear “money grab.” “It’s incomprehensible how a health insurance company could so blatantly continue to prioritize their profits over safe patient care,” he said. “If Anthem is, in fact, rescinding the policy, we’re delighted that they came to their senses.” Prior to Anthem’s announcement Thursday, Connecticut comptroller Sean Scanlon said the “concerning” policy wouldn’t affect the state after conversations with the insurance company. And New York Gov. Kathy Hochul said in an emailed statement Thursday that her office had also successfully intervened. The insurance giant’s policy change came one day after the CEO of UnitedHealthcare , another major insurance company, was shot and killed in New York City.
Anthem Blue Cross Blue Shield reverses decision to put a time limit on anesthesia
King laughs at British comedian’s impression of Donald Trump at Royal Variety
Marks & Spencer (M&S) will demolish its flagship Oxford Street store after three years of planning delays over the art deco building. Plans to rejuvenate the building as a nine-storey retail space, cafe, gym and office will now go ahead after housing secretary Angela Rayner gave the go-ahead. M&S says its new store will rank among the top 1 per cent of buildings in London on sustainable performance, will have a design life of 120 years and carbon payback within 11 years of construction. After opposition from sustainability and heritage experts led to years of legal wrangling, former housing secretary Michael Gove stepped in to refuse the application in July 2023. . M&S CEO Stuart Machin said: “I am delighted that, after three unnecessary years of delays, obfuscation and political posturing at its worst under the previous Government, our plans for Marble Arch – the only retail-led regeneration proposal on Oxford Street – have finally been approved. “We can now get on with the job of helping to rejuvenate the UK’s premier shopping street through a flagship M&S store and office space which will support 2,000 jobs and act as a global standard-bearer for sustainability. “At M&S, we share the Government’s ambition to breathe life back into our cities and towns and are pleased to see they are serious about getting Britain building and growing. We will now move as fast as we can.” Orchard House, the building M&S will demolish, was constructed in the late 1920s on the Marble Arch end of Oxford Street. M&S opened their flagship store in the building in 1930, before applying to Westminster City council for permission to demolish it in 2021. After Mr Gove rejected the plans in July 2021, a high court judge ruled that the government had made a series of flawed decisions in blocking the plans. On Thursday, Ms Rayner granted permission for the demolition and reconstruction of the building.CORAL GABLES, Fla. – Hitting the road for its second true away game of the season, No. 17 North Carolina picked up its first win in Coral Gables since 2015, toppling Miami 69-60 on its home court from the Watsco Center on Sunday afternoon. The Tar Heels open ACC action on the road with a win for the second straight season. Taking excellent care of the ball with a season low four turnovers, North Carolina (13-2, 1-1 ACC) handed Miami (11-2, 1-1 ACC) its second loss of the season off of an efficient day in the paint. The duo of Maria Gakdeng and Alyssa Ustby packed it in the paint with the two each recording a double-double. Gakdeng tied her season-high with 21 points and added a season-best 12 rebounds for her second double-double of the year. With her fourth on the season, Ustby tallied 19 points and 13 rebounds as she moved into No. 22 overall in scoring at UNC. Holding Miami to its fewest points this season, UNC's defense continues to make its opponents pay as the Tar Heels have now held 10 of its 15 opponents to their lowest point total this year. With a season-high and team best five assists, Indya Nivar reached double-figures for the sixth time this season as Carolina dished out 18 assists off 27 made field goals. Defense jumped on the Hurricanes early, forcing Miami into a multi-minute drought without a field goal for over half the first quarter. Gakdeng proved to be a problem in the paint with her most points in a quarter this season at nine, as Carolina ran out to a 21-14 lead over Miami through one. Pouring it on in the paint, the Tar Heels took advantage of the Hurricanes on the inside with 24 points in the first two quarters to extend its advantage. Despite Carolina surrendering the ball only three times in the opening half, Miami ended the second on a 7-0 run for UNC to take a 39-29 lead into the break. The trio of Gakdeng, Nivar and Ustby kept the Tar Heels in motion, working their way through the Hurricanes to dominate on the inside. The Hurricanes cut into UNC's advantage within seven, yet Carolina fired back to jump back ahead by double-digits at 62-47 with 10 minutes remaining. Both teams went cold from the floor in the opening minutes of the final quarter, yet Carolina limited Miami's chances at a potential comeback. Slowing down the game, UNC came away with the 69-60 victory and its first ACC win of the season. The Tar Heels head back to Chapel Hill, welcoming a No. 3 Notre Dame squad to Carmichael Arena next Sunday (Jan. 5). Carolina begins the new year at home against the Fighting Irish at 1 p.m. ET on ESPN.
Public Education Foundation Launches CCSD Alumni of the Year Award by Honoring Bo Bernhard, PhD and Alex Bybee at the Golden Apple GalaManchester City, Arsenal, and now Tottenham. The list of top Premier League teams beaten at Bournemouth this season is growing. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get updates and player profiles ahead of Friday's high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a weekCRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $
Volvo T5 Vs. T6: What's The Difference Between These Engines?Jessica Ennis-Hill shares top tips on how to fit in exercise around the workdayTrump asks Supreme Court to delay TikTok ban so he can weigh in after he takes office